China and Korea have contributed $4 million to the Africa Centres for Disease Control and Prevention (Africa CDC) to help ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Vimkunya™, a recombinant chikungunya vaccine, ...

Less than a week after newly confirmed Department of Health and Human Services (HHS) secretary Robert F. Kennedy Jr. | Less than a week after newly confirmed HHS secretary Robert F. Kennedy Jr.

As global markets continue to navigate a landscape marked by rising inflation and cautious monetary policy adjustments, small-cap stocks have been trailing behind their large-cap counterparts, with ...

Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...

The FDA has approved Bavarian Nordic’s Vimkunya, the first virus-like particle (VLP) chikungunya vaccine for patients over 12 years of age. According to the company, approval was based on strong ...

Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.

The US Food and Drug Administration (FDA) has approved Bavarian Nordic’s chikungunya vaccine Vimkunya for use in individuals ...

With the U.S. FDA’s approval of Vimkunya, Bavarian Nordic A/S is now in the chikungunya virus infection mix along with Valneva SE’s Ixchiq. A single-dose, adjuvanted virus-like particle-based vaccine ...

As a bonus, Bavarian Nordic also gets a priority review voucher from the FDA, awarded as an incentive to carry out drug ...

Bavarian Nordic sets up a bout with Valneva’s Ixchiq, the former’s Vimkunya already having an edge in population reach.